請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6601
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳 | |
dc.contributor.author | Chang-Hsueh Wu | en |
dc.contributor.author | 吳昌學 | zh_TW |
dc.date.accessioned | 2021-05-17T09:15:08Z | - |
dc.date.available | 2012-09-18 | |
dc.date.available | 2021-05-17T09:15:08Z | - |
dc.date.copyright | 2012-09-18 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-13 | |
dc.identifier.citation | 1. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005;5:88.
2. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66. 3. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009;9:44. 4. Swoboda S, Ober M, Hainer C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008;61:729-33. 5. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010;50:229-38. 6. FDA drug safety communication: Increased risk of death with Tygacil(Tigecycline) compared to other antibiotics used to treat similar infections.(Accessed 8 April 2011, at http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.) 7. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71. 8. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-9. 9. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Protein synthesis inhibitorsand miscellaneous antibacterial agents. In: Goodman & Gilman's pharmacological basis of therapeutics. 12 th ed. New York: McGraw-Hill; 2011. 10. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71. 11. Tygacil(TM), tigecycline for injection. Wyeth Pharmaceuticals, Philadelphia, PA, USA. 2010.(Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf ) 12. K. R, M. G, M. C, J. K-B, G. D, E. E-G. Tigeycline(TGC) concentration(Cp) in lung tissue, cerebrospinal fluid(CSF) , and bile of human subjects. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2005. 13. Conte JE, Jr., Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9. 14. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007;35:1543-53. 15. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline(GAR-936). Antimicrob Agents Chemother 1999;43:738-44. 16. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20:219S-23S. 17. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines(GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9. 18. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9. 19. Nicolau DP, Mengedoht DE, Kline JJ. Tetracycline-induced pancreatitis. Am J Gastroenterol 1991;86:1669-71. 20. Elmore MF, Rogge JD. Tetracycline-induced pancreatitis. Gastroenterol 1981;81:1134-6. 21. Steinberg WM. Acute drug and toxin induced pancreatitis. Hosp Pract(Off Ed) 1985;20:95-102. 22. Gilson M, Moachon L, Jeanne L, et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand J Infect Dis 2008;40:681-3. 23. Mascarello M, Papa G, Arnez ZM, Luzzati R. Acute necrotizing pancreatitis related to tigecycline. J Antimicrob Chemother 2012;67:1296-7. 24. Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 2009;34:486-9. 25. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41 Suppl 5:S315-32. 26. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-14. 27. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-61. 28. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41:S341-S53. 29. Darling IM, Cirincione BB, Owen JS. Noncompartmental pharmacokinetics of tigecycline in phase 3 studies of patients with complicated skin and skin-structure and intra-abdominal infections. In: Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA: American Society for Microbiology; 2005:17. 30. Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Ambrose PG. Estimation of in vitro susceptibility breakpoints for tigecycline against staphylococci. In: Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA: American Society for Microbiology; 2005:22. 31. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008;62 Suppl 1:i11-6. 32. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41 Suppl 5:S354-67. 33. Chen Z, Wu J, Zhang Y, et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010;10:217. 34. Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Ambrose PG. Estimate of in vitro usceptibility breakpoint for tigecycline against Enterobacteriaeae. In: Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA: American Society for Microbiology; 2005:23. 35. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. 36. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005;52:187-93. 37. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-38. 38. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63:52-61. 39. Rubino CM, Bhavnani SM, Forrest A, Korth-Bradley J, Ambrose PG. Pharmacokinetic-pharmacodynamic analysis for efficacy of tigecycline in patients with hospital- or community-acquired pneumonia. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago(IL), USA: Institute For Clinical Pharmacodynamics; 2007. 40. McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs 2008;68:2633-44. 41. The European Committee on Antimicrobial Susceptibility Testing - EUCAST. 2012.(Accessed January 1st, 2012, at http://www.eucast.org/.) 42. Liu JW, Ko WC, Huang CH, et al. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan(TIST) study, 2008 to 2010. Antimicrob Agents Chemother 2012;56:1414-7. 43. Kao T-M, Wang J-T, Weng C-M, Chen Y-C, Chang S-C. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006–2008: Stratified analysis by vancomycin MIC. J Microbiol Immunol Infect 2011;44:346-51. 44. Chen YH, Lu PL, Huang CH, et al. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob Agents Chemother 2012;56:1452-7. 45. Kandemir O, Oztuna V, Colak M, Akdag A, Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53-7. 46. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51. 47. Dowzicky MJ, Chmelařova E. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int J Antimicrob Agents 2011;37:562-6. 48. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: Successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-4. 49. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62 Suppl 1:i17-28. 50. Eckmann C, Heizmann WR, Leitner E, von Eiff C, Bodmann KF. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy 2011;57:275-84. 51. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010;54:2735-7. 52. Samonis G, Karageorgopoulos DE, Maraki S, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PloS one 2012;7:e37375. 53. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65:288-99. 54. Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008;54:91-100. 55. Ye J, Jr., Lin H-S, Kuo A-J, et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011;63:351-61. 56. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7. 57. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine(Baltimore) 2009;88:211-20. 58. Kuo SC, Wang FD, Fung CP, et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011;44:45-51. 59. Curcio D, Vargas SW, Ugarte Ubiergo S, et al. Tigecycline treatment of critically ill patients: the Latin user experience. Curr Clin Pharmacol 2011;6:18-25. 60. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010;10:287. 61. Tasina E, Haidich A-B, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44. 62. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. 63. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. 64. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther 1981;30:239-45. 65. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64. 66. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. 67. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406. 68. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. 69. Mosby's medical dictionary. St. Louis: Mosby/Elsevier; 2006. 70. Annane D, Bellissant E, Cavaillon J-M. Septic shock. Lancet 2005;365:63-78. 71. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39. 72. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24. 73. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. 74. Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: Importance of healthcare-associated infections. J Infect 2008;56:27-34. 75. What is a Serious Adverse Event?(Accessed 07/31, 2012, at http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.) 76. Klare B, Kubini R, Ewig S. Risk factors for pneumonia in patients with cardiovascular diseases. Pneumologie 2002;56:781-8. 77. Matsui T, Ebihara T, Ohrui T, Yamaya M, Arai H, Sasaki H. Cerebrovascular disease and pneumonia in the elderly. Nihon Ronen Igakkai Zasshi 2003;40:325-8. 78. Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe(2004–2007). Int J Antimicrob Agents 2009;34:121-30. 79. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80. 80. Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58:273-84. 81. Curcio D, Fernandez F, Cane A, Barcelona L, Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008;12:198-201. 82. Garcia-Cabrera E, Jimenez-Mejias M, Gil Navarro M, et al. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010;29:867-71. 83. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009;34:101-2. 84. Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother 2010;54:1207-12. 85. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012;56:1065-72. 86. Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 2005;25:963-76. 87. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97. 88. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-48. 89. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821-7. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6601 | - |
dc.description.abstract | 研究背景:
Tigecycline目前已被美國食物藥品管理局認可在複雜性腹腔內感染、複雜性皮膚及皮膚結構感染的治療及社區型肺炎的治療;在許多體外試驗發現,tigecycline對許多抗藥性細菌具有敏感性,因此在臨床上常拿來作為對抗抗藥性細菌的藥品,但美國食物藥品管理局在2010年發布警訊,使用tigecycline的病人比對照組藥品有死亡率上升之趨勢,特別是在院內感染肺炎,治療失敗率及發生敗血性休克的人數較多,所以不建議在感染較嚴重的病人使用。 研究目的: 評估在使用tigecycline病人的臨床治療成效及死亡率,並分析單純肺炎感染病人的臨床治療成效及死亡率,此外分析治療失敗之危險因子及使用之菌種分布,統計使用此藥品常見之副作用。 研究方法: 本研究為回溯性研究,研究之病人群為2010年1月至2011年6月曾於某醫學中心,有使用tigecycline之病人,且有感染症相關診斷者,排除年齡小於20歲及資料不全者;以電子病歷及紙本病歷收集資料,其主要內容包含病人基本資料、潛在疾病、疾病嚴重度、使用tigecycline時的臨床表徵及相關檢驗數值、使用前後的菌種培養及續發性感染之菌種分布、臨床治療成果以及治療期間發生之不良反應;不同病人的臨床治療反應以卡方檢定分析,使用羅吉斯迴歸分析所有病人以及單純肺炎感染病人治療失敗的獨立危險因子。 研究結果: 本研究共收入137人,多重感染者有61人(44.5%),其中60人(43.8%) 感染肺炎;單一感染症者有76人(55.5%),單純感染肺炎者有71人(51.8%),複雜性腹腔內感染者有11人(8%),複雜性皮膚及皮膚結構感染者5人(3.6%);潛在疾病以呼吸系統疾病(80%)、腎臟疾病(71%)及心臟疾病(61%)最多;治療之菌種最常見為Multidrug-resistant Acinetobacter baumannii(MDRAB)71%,其次是Stenotrophomonas maltophilia 7%,大多菌種為多重抗藥性之細菌,此外MDRAB的tigecycline敏感性在本研究為67%。 治療結果整體看來有50%的臨床治療反應成功率,在單純肺炎的病人與複雜性腹腔內感染及複雜性皮膚及皮膚結構感染相比有較低的臨床治療成功率(pneumonia: 45% vs cIAIs:100%和cSSSIs:64%),在單一菌種感染也比多重菌種感染臨床治療反應好(59% vs 39%, P值0.0241),tigecycline敏感性之菌種有較好之臨床治療反應(54% vs 32%, P值0.0414);此外本研究發生續發性感染的機率為37%,最常見之續發性感染菌種為Pseudomonas aeruginosa約有10%。 在全體病人中,治療時之血糖大於180 mg/dL(OR 3.28, P=0.0395)、在使用tigecycline時發生敗血性休克(OR 3.34, P=0.002)、在使用tigecycline時發生急性腎衰竭(OR 2.40, P=0.0416)為造成治療失敗的獨立危險因子;在單純肺炎感染之病人,使用tigecycline時發生敗血性休克(OR 5.04, P=0.0078)為tigecycline治療失敗之獨立危險因子。 本研究常見之副作用為腸胃道副作用(35%),腸胃道副作用中以腹瀉最多(21%),噁心及嘔吐的副作用各4%。 結論: 不管是全體病人或單純肺炎感染的獨立危險因子分析,均發現疾病嚴重程度以及血糖值與治療失敗有相關,因此疾病嚴重程度越高,血糖控制越差者,治療越容易失敗;不過在死亡率則和文獻顯示相近,並無較高之死亡率;在副作用方面以腸胃道副作用最多,腸胃道副作用中最常發生之副作用為腹瀉,噁心及嘔吐發生的比例較之前研究低。 | zh_TW |
dc.description.abstract | Background:
Tigecycline is approved by the USA Food and Drug Administration(FDA) for the treatment of complicated intra-abdominal infections(cIAIs), complicated skin and skin structure infections(cSSSIs), and community acquired pneumonia(CAP). Tigecycline is active against many resistant pathogens in in-vivo study, and it can be used for the antibiotic-resistant bacterial infections. However, FDA imposed a black box warning on tigecycline in 2010. Concerning the increasing mortality rate of tigecycline, especially in the treatment of hospital-acquired pneumonia, in clinical trials and retrospective studies. In addition, patients treated by tigecycline have significant more treatment failure and septic shock. Therefore, tigecycline is not recommended in critically ill patients. Objective: The goal of this study is to evaluate the clinical response and mortality of patients receiving tigecycline treatment in Taiwan. The clinical response and mortality of patients with pneumonia only are analyzed in sub-group analysis, identifying the risk factors for treatment failure and the indicated pathogens assessed. We also evaluate the adverse drug reactions of tigecycline. Methods: This retrospective study included patients hospitalized in a 2500-bed medical center with infection-related diagnosis and received tigecycline between January 2010 and June 2011. Patients younger than 20 years old or with incomplete data are excluded. We reviewed the medical records including baseline characteristics, comorbidities, disease severity, clinical presentations, laboratory data, culture results, pathogens of secondary infection, clinical response, and adverse drug reactions of tigecycline. Treatment outcomes in different groups were analyzed by chi-square test. We also identified the risk factors for treatment failure in all patients and in patients with pneumonia only by logistic regression. Results: Among 137 patients, 61(44.5%)patients had multiple-site infection, 71(51.8%) patients had pneumonia with other infections, 76(55.5%)patients had mono-site infection, 60 patients had pneumonia only, 11(8%) patients had cIAIs, and 5(3.6%) patients had cSSSIs. Most patients had comorbid respiratory diseases(80%), renal diseases(71%), and cardiovascular diseases(61%). The most common indicated pathogens were multidrug-resistant Acinetobacter baumannii(MDRAB)(71%), and Stenotrophomonas maltophilia(7%). The susceptibility of MDRAB was approximately 67% in this study. Overall clinical response was 50%. Clinical response in patients with pneumonia only was 45%, which is lower than patient with cIAIs or cSSSIs only(100% and 64%, respectively).Patients with mono-microbial infection had higher clinical response than those with poly-microbial infection(59% vs 39%, P=0.0241). Besides, the susceptible pathogens also had better clinical response(54% vs 32%, P=0.0414). Fifty-one patients(37%) had secondary infections in total, and the most common pathogen was Pseudomonas aeruginosa(10%). In total patients, blood sugar higher than 180 mg/dL during tigecycline treatment(OR 3.28, P=0.0395), septic shock at the first day of tigecycline used(OR 3.34, P=0.002), and acute kidney injury at the first day of tigecycline used(OR 2.40, P=0.0416) were independent risk factors for treatment failure. In patients with pneumonia only, the independent risk factors were septic shock at the first day of tigecycline used(OR 5.04, P=0.0078). In this study, the most common side effects were gastrointestinal(GI) side effects(35%), and diarrhea(21%) is the most frequently. In contrast to previous studies, nausea and vomiting were reported both only 4%in this study. Conclusion: Patients’ disease severity is correlated with treatment outcomes, regardless in all patients or in patients with pneumonia only. There would be more treatment failure in patients with severe disease status and in patients with hyperglycemia. However, the mortality rate is similar with other studies. The most adverse drug reactions of tigecycline are gastrointestinal tract side effects. Among gastrointestinal tract side effects, diarrhea is the most common side effects. Percentage of nausea and vomiting is less than prior studies. | en |
dc.description.provenance | Made available in DSpace on 2021-05-17T09:15:08Z (GMT). No. of bitstreams: 1 ntu-101-R99451010-1.pdf: 1001188 bytes, checksum: e6e93f37def35eabdee26c4f8f29122f (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract iv 目錄 vii 表目錄 ix 圖目錄 xi 縮寫表 xii 第1章 前言 1 第2章 文獻探討 2 2.1 藥品性質 2 2.2 Tigecycline使用劑量 6 2.3 Tigecycline在臨床上核可的適應症 7 2.4 抗藥性細菌之治療 12 2.5 臨床嚴重感染及院內感染肺炎之病人 15 2.6 美國食品藥物管理局(The Food and Drug Administration, FDA)警告以及其他研究之統合分析 16 第3章 研究目的 18 第4章 研究方法 19 4.1 研究設計 19 4.2 研究之時間、地點與對象 20 4.3 資料收集 20 4.4 名詞定義 23 4.5 統計分析方法 29 第5章 研究結果 30 5.1 收案流程 30 5.2 病人基本資料 31 5.3 Tigeycline治療之主要菌種分佈 34 5.4 Tigecycline之敏感性試驗 35 5.5 治療結果 36 5.6 存活分析 45 5.7 危險因子分析 49 5.8 續發性感染之菌種分布 62 5.9 副作用 64 第6章 討論 66 6.1 使用tigecycline的族群分析 66 6.2 菌種之分佈及敏感性 67 6.3 使用tigecycline治療結束時的死亡率 69 6.4 治療結果 71 6.5 續發性感染 73 6.6 危險因子分析 74 6.7 副作用 76 6.8 研究限制 77 第7章 結論 79 第8章 參考文獻 81 附件 個案報告表(Case report form) 90 | |
dc.language.iso | zh-TW | |
dc.title | Tigecycline在感染症之臨床治療成效及副作用 | zh_TW |
dc.title | The clinical treatment outcomes and side effects of tigecycline in infectious diseases | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林慧玲,林淑文,盛望徽,王振泰 | |
dc.subject.keyword | Tigecycline,死亡率,臨床治療反應,治療失敗危險因子,副作用, | zh_TW |
dc.subject.keyword | Tigecycline,mortality,clinical response,risk factors for treatment failure,side effects, | en |
dc.relation.page | 102 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2012-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf | 977.72 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。